-
ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference,…
-
Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma
In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian…
-
Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024
In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked…
-
Dr. Charles E. Geyer, Jr.: Atezolizumab in TNBC – Insights from the NSABP B-59/GBG-96-GeparDouze Trial
Dr. Charles Geyer, Jr.. presented findings from the NSABP B-59/GBG-96-GeparDouze phase III trial, evaluating the addition of atezolizumab to neoadjuvant chemotherapy, followed by adjuvant atezolizumab, in stage II-III triple-negative breast cancer (TNBC).
-
EORTC-1203 GITC “INNOVATION”: Evaluating HER2-Targeted Perioperative Therapy in Stomach Cancer
At ASCO GI 2025, Anna Dorothea Wagner and colleagues presented the EORTC-1203 “INNOVATION” trial, investigating trastuzumab (T) ± pertuzumab (P) with perioperative chemotherapy (CT) in HER2+ gastric and esophagogastric junction…
-
CheckMate 8HW: Dual Immunotherapy Improves Outcomes in MSI-H/dMMR mCRC
At ASCO GI 2025, Thierry André and colleagues presented CheckMate 8HW results, showing nivolumab (NIVO) + ipilimumab (IPI) outperforms NIVO alone in MSI-H/dMMR metastatic colorectal cancer (mCRC). Key findings:✅ PFS…
-
BREAKWATER Trial: Advancing First-Line Therapy for BRAF V600E-Mutant Colorectal Cancer
A new phase 3 study, led by Scott Kopetz and an international team, provides strong evidence supporting encorafenib + cetuximab (EC) with mFOLFOX6 as a first-line treatment for BRAF V600E-mutant…
-
Yelena Janjigian Leads Advances in HER2+ Gastroesophageal Cancer Treatment
At ASCO GI 2025, Yelena Janjigian and colleagues presented DESTINY-Gastric03 (DG-03) trial results, evaluating trastuzumab deruxtecan (T-DXd) with fluoropyrimidine (FP) and pembrolizumab as first-line therapy for advanced HER2+ gastric, esophageal,…
Connecting Medical Expertise through Media